Hepatitis B in Nigeria 2025
The Silent Epidemic 8% of You Are Living With

Why Nigeria Has One of the World's Highest Hepatitis B Rates

Hepatitis B virus (HBV) infects the liver and can cause chronic infection leading to cirrhosis and liver cancer. Nigeria's burden, estimated at 8–11% carrier prevalence, reflects the predominant transmission route: mother-to-child at birth and early childhood horizontal transmission (through cuts, shared razors, or close household contact).

Unlike HIV (where transmission typically occurs in adulthood and the adult immune system mounts a partial response), HBV acquired in early childhood becomes chronic in 90% of cases, because the immature immune system cannot clear it. The result is millions of Nigerians carrying a liver-damaging virus they acquired before they could walk.

The Lifecycle of Hepatitis B, and When It Becomes Dangerous

After infection, HBV goes through distinct phases:

• Immune-tolerant phase: High viral replication, normal liver enzymes, minimal liver damage. Can last decades. Most carriers are in this phase and feel completely well.
• Immune-active phase: The immune system attacks infected liver cells, causing elevated liver enzymes and progressive inflammation. This is when antiviral treatment is most indicated.
• Inactive carrier phase: Low viral replication, normal liver enzymes. Liver damage from the immune-active phase may have occurred.
• Reactivation: Inactive carriers can reactivate: particularly during immunosuppression (chemotherapy, steroids, HIV), causing sudden severe hepatitis.

The transition from carrier to liver cancer (hepatocellular carcinoma: HCC) typically takes 20–40 years of chronic inflammation. Nigeria has extremely high rates of HCC, the majority attributable to HBV. Annual ultrasound monitoring of the liver in HBV carriers is the intervention that detects HCC when it is still resectable.

Testing and Vaccination: the Two Interventions That Eliminate Risk

Testing

A full hepatitis B profile (HBsAg, anti-HBs, HBeAg, anti-HBe, anti-HBc) tells you whether you are: currently infected, immune from past infection, immune from vaccination, or susceptible (never infected and never vaccinated). This one blood panel determines your entire management pathway.

Vaccination

The hepatitis B vaccine is one of the most effective vaccines in existence, providing >95% protection against HBV infection. Three doses are required. For non-immune adults in Nigeria, vaccination is urgently recommended, particularly healthcare workers, household contacts of carriers, and anyone with a new sexual partner.

Antiviral treatment

Tenofovir and entecavir suppress HBV replication to undetectable levels, preventing progressive liver damage. Not all carriers need treatment, the decision is based on HBV DNA, ALT level, and liver biopsy/fibroscan results. Annual monitoring is required for all carriers, with treatment started when indicated criteria are met.

About this article: Written by the Mascot Healthcare clinical team. This article is reviewed annually and updated to reflect current guidelines and data.